Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 6/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280678 | 1.00 | PIN1 (0.59) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL30042883 | 1.00 | PIN1 (0.59) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL5875699 | 1.00 | PIN1 (0.59) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL7211356 | 0.85 | CHRM1 (0.62) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL5325374 | 0.85 | CHRM1 (0.62) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL11100952 | 0.84 | KDM4E (0.59) | PIN1KDM4ERAB9ACYP1A2ALDH1A1 | |
| SCHEMBL6530115 | 0.83 | MAPT (0.59) | PIN1CHRM1KDM4ERAB9AALDH1A1 | |
| SCHEMBL38661628 | 0.82 | PIN1 (0.62) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL15156683 | 0.82 | PIN1 (0.62) | PIN1CHRM1KDM4ERAB9AGAA | |
| SCHEMBL17771956 | 0.81 | KDM4E (0.51) | PIN1KDM4EGAACYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727991-A | Ras inhibitory peptide | 一丸自然美健有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | claimed |
| US-20250186540-A1 | VIPR2 ANTAGONIST PEPTIDE FOR SUPPRESSING CANCER METASTASIS | ICHIMARU PHARCOS CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4541891-A1 | NOVEL LRP1-BINDING PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2025-04-23 | — | — | EP | disclosed |
| EP-4473973-A1 | VIPR2 ANTAGONIST PEPTIDE FOR SUPPRESSING CANCER METASTASIS | Ichimaru Pharcos Co., Ltd. (JP) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024111590-A1 | COMPOSITION CONTAINING RAS INHIBITOR PEPTIDE | 一丸ファルコス株式会社 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024029242-A1 | NOVEL LRP1-BINDING PEPTIDE | 一丸ファルコス株式会社 | 2024-02-08 | — | — | WO | disclosed |
| WO-2023190812-A1 | VIPR2 ANTAGONIST PEPTIDE FOR CANCER IMMUNOPOTENTIATION | 国立大学法人香川大学 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023162456-A1 | VIPR2 ANTAGONIST PEPTIDE FOR SUPPRESSING CANCER METASTASIS | 一丸ファルコス株式会社 | 2023-08-31 | — | — | WO | disclosed |
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4137502-A1 | VIPR2 ANTAGONIST PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2023-02-22 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0371390-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1990-06-06 | — | — | EP | disclosed |
| EP-0342325-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-23 | — | — | EP | disclosed |
| EP-0330925-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-09-06 | — | — | EP | disclosed |
| EP-0309841-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0286813-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-10-19 | — | — | EP | disclosed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | VIPR2, NPY2R, NPY5R | PIN1 1541/4885CHRM1 612/4885KDM4E 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.